Kay Khine Soe

Kay Khine Soe

Assistant Professor

UCSI University

Profile ID RP-002-9062 Joined 2024-09-17 2 articles
0Connections
6
Total Views
2
Total Publications
55
Publication Views

Articles(2)

Authors: Kay Khine Soe, Thanachit Krikeerati, Chatkamol Pheerapanyawaranun, Suvimol Niyomnaitham, Phichayut Phinyo, Torpong Thongngarm

DOI: 10.3389/fphar.2023.1184552

Volume14
Issue14
Pages01-15
Abstract

No evidence shows that one intranasal corticosteroid (INCS) is better than another for treating moderate-to-severe allergic rhinitis (AR). This network meta-analysis assessed the comparative efficacy and acceptability of licensed dose aqueous INCSs. PubMed/MEDLINE, Scopus, EMBASE, and the Cochrane Central Register of Controlled Trials were searched until 31 March 2022. Eligible studies included randomized controlled trials comparing INCSs with placebo or other types of INCSs in patients with moderate-to-severe allergic rhinitis. Two reviewers independently screened and extracted data following the Preferred Reporting Items in Systematic Reviews and Meta-analysis guideline. A random-effects model was used for data pooling. Continuous outcomes were expressed as standardized mean difference (SMD). The primary outcomes were the efficacy in improving total nasal symptom score (TNSS) and treatment acceptability (the study dropout). We included 26 studies, 13 with 5,134 seasonal AR patients and 13 with 4,393 perennial AR patients. Most placebo-controlled studies had a moderate quality of evidence. In seasonal AR, mometasone furoate (MF) was ranked the highest efficacy, followed by fluticasone furoate (FF), ciclesonide (CIC), fluticasone propionate and triamcinolone acetonide (TAA) (SMD −0.47, 95% CI: −0.63 to −0.31; −0.46, 95% CI: −0.59 to −0.33; −0.44, 95% CI: −0.75 to −0.13; −0.42, 95% CI: −0.67 to −0.17 and −0.41, 95% CI: −0.81 to −0.00), In perennial AR, budesonide was ranked the highest efficacy, followed by FF, TAA, CIC, and MF (SMD −0.43, 95% CI: −0.75 to −0.11; −0.36, 95% CI: −0.53 to −0.19; −0.32, 95% CI: −0.54 to −0.10; −0.29, 95% CI: −0.48 to −0.11; and −0.28, 95% CI: −0.55 to −0.01). The acceptability of all included INCSs was not inferior to the placebo. According to our indirect comparison, some INCSs have superior efficacy to others with moderate quality of evidence in most placebo-controlled studies for treating moderate-to-severe AR.

No matching articles

Try another word from the title, author or DOI.

Brief Bio

No bio added yet.

Affiliations

Nothing added yet.

Education

Nothing added yet.

Honors & Awards

Nothing added yet.

Society Memberships

Nothing added yet.

Expertise

Nothing added yet.

Specialty

Nothing added yet.

Other Online Pages

Scholars in the same field

AS
ankit Singh singh
0 publications
VG
Vineeta Gupta
0 publications
NA
Niyati Airan
Veer Chandra Singh Garhwali Government Institute of Medical Science and Research, Srinagar Garhwal, Uttarakhand.
0 publications
SB
Sudip Bhattacharjee
0 publications
ZB
Zenish Bhatti
0 publications
DL
Dhanya Leelamony
0 publications
SK
Surendra Kumar Pal
0 publications
SR
Sharif Ratul Hassan
Northern University Bangladesh
0 publications
MN
Mohammad Nasir
0 publications
Dr Sameer Dileep Joshi
LNBCIEM Satara Maharashtra
0 publications
AK
Ajay Kumar Singha
0 publications

Following

Nobody here yet.

Followers

Nobody here yet.

2 Publications

0 Contributions

Nothing added yet.

Filter